Interplay of Obesity, Ethanol, and Contaminant Mixture on Clinical Profiles of Cardiovascular and Metabolic Diseases: Evidence from an Animal Study.
Cardiovascular and metabolic diseases
Clinical markers
Contaminants
Ethanol
Obesity
Journal
Cardiovascular toxicology
ISSN: 1559-0259
Titre abrégé: Cardiovasc Toxicol
Pays: United States
ID NLM: 101135818
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
20
10
2021
accepted:
28
03
2022
pubmed:
17
4
2022
medline:
18
5
2022
entrez:
16
4
2022
Statut:
ppublish
Résumé
Obesity, ethanol, and contaminants are known risk factors of cardiovascular and metabolic diseases (CMD). However, their interplay on clinical profiles of these diseases remains unclear, and thus were investigated in this study. Male lean or obese JCR rats were given water or 10% ethanol and orally treated with or without a contaminant mixture (CM) dissolved in corn oil and loaded on two cookies at 0, 1.6, or 16 mg/kg BW/day dose levels for 4 weeks. The CM consisted 22 environmental contaminants found in human blood or serum of Northern populations. Over 60 parameters related to CMD were examined. The results revealed that obesity in JCR rats resembles the clinical profiles of non-alcoholic fatty liver disease in humans. Obesity was also associated with increased serum and organ retention of mercury, one of the chemical components of CM. Exposure to ethanol lightened hyperlipidemia, increased liver retention of mercury, and increased risk for hypertension in the obese rats. CM lessened hyperlipidemia and hyperenzymemia, worsened systemic inflammation and increased the risk for hypertension in the obese rats. CM markedly increased serum ethanol levels with or without ethanol exposure. Tissue total mercury contents significantly correlated with clinical parameters with altered profiles by both ethanol and obesity. These results suggest that obese individuals may be more prone to contaminant accumulation. Ethanol and CM exposure can alter clinical profiles associated with obesity, which may lead to misdiagnosis of CMD associated with obesity. CM can alter endogenous production and/or metabolism of ethanol, further complicating disease progression, diagnosis, and treatment.
Identifiants
pubmed: 35429258
doi: 10.1007/s12012-022-09738-6
pii: 10.1007/s12012-022-09738-6
pmc: PMC9107407
doi:
Substances chimiques
Ethanol
3K9958V90M
Mercury
FXS1BY2PGL
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
558-578Informations de copyright
© 2022. Crown.
Références
Thomas, M. R., & Lip, G. Y. (2017). Novel risk markers and risk assessments for cardiovascular disease. Circulation Research, 120(1), 133–149. https://doi.org/10.1161/CIRCRESAHA.116.309955
doi: 10.1161/CIRCRESAHA.116.309955
pubmed: 28057790
Stegemann, C., Pechlaner, R., Willeit, P., Langley, S. R., Mangino, M., Mayr, U., Menni, C., Moayyeri, A., Santer, P., Rungger, G., Spector, T. D., Willeit, J., Kiechl, S., & Mayr, M. (2014). Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. Circulation, 129(18), 1821–1831. https://doi.org/10.1161/CIRCULATIONAHA.113.002500
doi: 10.1161/CIRCULATIONAHA.113.002500
pubmed: 24622385
Shapiro, M. D., & Fazio, S. (2016). From lipids to inflammation: New approaches to reducing atherosclerotic risk. Circulation Research, 118(4), 732–749. https://doi.org/10.1161/CIRCRESAHA.115.306471
doi: 10.1161/CIRCRESAHA.115.306471
pubmed: 26892970
Ruparelia, N., Chai, J. T., Fisher, E. A., & Choudhury, R. P. (2017). Inflammatory processes in cardiovascular disease: A route to targeted therapies. Nature Review of Cardiology., 14(3), 133–144. https://doi.org/10.1038/nrcardio.2016.185
doi: 10.1038/nrcardio.2016.185
Moriya, J. (2019). Critical roles of inflammation in atherosclerosis. Journal of Cardiology., 73(1), 22–27. https://doi.org/10.1016/j.jjcc.2018.05.010
doi: 10.1016/j.jjcc.2018.05.010
pubmed: 29907363
Anderson, T. J., Grégoire, J., Pearson, G. J., Barry, A. R., Couture, P., Dawes, M., Francis, G. A., Genest, J., Jr., Grover, S., Gupta, M., Hegele, R. A., Lau, D. C., Leiter, L. A., Lonn, E., Mancini, G. B., McPherson, R., Ngui, D., Poirier, P., Sievenpiper, J. L., … Ward, R. (2016). Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can Journal of Cardiology., 32(11), 1263–1282. https://doi.org/10.1016/j.cjca.2016.07.510
doi: 10.1016/j.cjca.2016.07.510
Gerhard-Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., Fleisher, L. A., Fowkes, F. G., Hamburg, N. M., Kinlay, S., Lookstein, R., Misra, S., Mureebe, L., Olin, J. W., Patel, R. A., Regensteiner, J. G., Schanzer, A., Shishehbor, M. H., Stewart, K. J., … Walsh, M. E. (2017). 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: Executive summary: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation, 135(12), e686–e725. https://doi.org/10.1161/CIR.0000000000000470
doi: 10.1161/CIR.0000000000000470
pubmed: 27840332
Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. (2020). 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk [published correction appears in Atherosclerosis. 292:160–162] published correction appears in Atherosclerosis. 294:80–82. Atherosclerosis (2019). 290, 140–205. https://doi.org/10.1016/j.atherosclerosis.2019.08.014 .
van Holten, T. C., Waanders, L. F., de Groot, P. G., Vissers, J., Hoefer, I. E., Pasterkamp, G., Prins, M. W., & Roest, M. (2013). Circulating biomarkers for predicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses. PLoS ONE, 8(4), e62080. https://doi.org/10.1371/journal.pone.0062080
doi: 10.1371/journal.pone.0062080
pubmed: 23630624
pmcid: 3632595
Montgomery, J. E., & Brown, J. R. (2013). Metabolic biomarkers for predicting cardiovascular disease. Vascular Health Risk Management., 9, 37–45. https://doi.org/10.2147/VHRM.S30378
doi: 10.2147/VHRM.S30378
pubmed: 23386789
pmcid: 3563347
Afari, M. E., & Bhat, T. (2016). Neutrophil to lymphocyte ratio (NLR) and cardiovascular diseases: An update. Expert Review of Cardiovascular Therapy, 14(5), 573–577. https://doi.org/10.1586/14779072.2016.1154788
doi: 10.1586/14779072.2016.1154788
pubmed: 26878164
Woodward, L., Akoumianakis, I., & Antoniades, C. (2017). Unravelling the adiponectin paradox: Novel roles of adiponectin in the regulation of cardiovascular disease. British Journal of Pharmacology., 174(22), 4007–4020. https://doi.org/10.1111/bph.13619
doi: 10.1111/bph.13619
pubmed: 27629236
Mandviwala, T., Khalid, U., & Deswal, A. (2016). Obesity and cardiovascular disease: A risk factor or a risk marker? Current Atherosclerosis Reports, 18(5), 21. https://doi.org/10.1007/s11883-016-0575-4
doi: 10.1007/s11883-016-0575-4
pubmed: 26973130
Vecchié, A., Dallegri, F., Carbone, F., Bonaventura, A., Liberale, L., Portincasa, P., Frühbeck, G., & Montecucco, F. (2018). Obesity phenotypes and their paradoxical association with cardiovascular diseases. European Journal of Internal Medicine, 48, 6–17. https://doi.org/10.1016/j.ejim.2017.10.020
doi: 10.1016/j.ejim.2017.10.020
pubmed: 29100895
Buckley, A. J., Thomas, E. L., Lessan, N., Trovato, F. M., Trovato, G. M., & Taylor-Robinson, S. D. (2018). Non-alcoholic fatty liver disease: Relationship with cardiovascular risk markers and clinical endpoints. Diabetes Research Clinical Practice, 144, 144–152. https://doi.org/10.1016/j.diabres.2018.08.011
doi: 10.1016/j.diabres.2018.08.011
pubmed: 30170074
Tana, C., Ballestri, S., Ricci, F., Di Vincenzo, A., Ticinesi, A., Gallina, S., Giamberardino, M. A., Cipollone, F., Sutton, R., Vettor, R., Fedorowski, A., & Meschi, T. (2019). Cardiovascular risk in non-alcoholic fatty liver disease: Mechanisms and therapeutic implications. International Journal of Environmental Research and Public Health, 16(17), 3104. https://doi.org/10.3390/ijerph16173104
doi: 10.3390/ijerph16173104
pmcid: 6747357
O’Keefe, J. H., Bybee, K. A., & Lavie, C. J. (2007). Alcohol and cardiovascular health: The razor-sharp double-edged sword. Journal of American Collage of Cardiology., 50, 1009–1014. https://doi.org/10.1016/j.jacc.2007.04.089
doi: 10.1016/j.jacc.2007.04.089
O’Keefe, E. L., DiNicolantonio, J. J., O’Keefe, J. H., & Lavie, C. J. (2018). Alcohol and CV health: Jekyll and Hyde J-curves. Progress in Cardiovascular Diseases, 61(1), 68–75. https://doi.org/10.1016/j.pcad.2018.02.001
doi: 10.1016/j.pcad.2018.02.001
pubmed: 29458056
Manolis, T. A., Manolis, A. A., & Manolis, A. S. (2019). Cardiovascular effects of alcohol: A double-edged sword/how to remain at the nadir point of the J-curve? Alcohol, 76, 117–129. https://doi.org/10.1016/j.alcohol.2018.08.011
doi: 10.1016/j.alcohol.2018.08.011
pubmed: 30735906
Barr, T., Helms, C., Grant, K., & Messaoudi, I. (2016). Opposing effects of alcohol on the immune system. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 65, 242–251. https://doi.org/10.1016/j.pnpbp.2015.09.001
doi: 10.1016/j.pnpbp.2015.09.001
pubmed: 26375241
Rapsomaniki, E., Timmis, A., George, J., Pujades-Rodriguez, M., Shah, A. D., Denaxas, S., White, I. R., Caulfield, M. J., Deanfield, J. E., Smeeth, L., Williams, B., Hingorani, A., & Hemingway, H. (2014). Blood pressure and incidence of twelve cardiovascular diseases: Lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. The Lancet, 383, 1899–1911. https://doi.org/10.1016/S0140-6736(14)60685-1
doi: 10.1016/S0140-6736(14)60685-1
Min, J. Y., Cho, J. S., Lee, K. J., Park, J. B., Park, S. G., Kim, J. Y., & Min, K. B. (2011). Potential role for organochlorine pesticides in the prevalence of peripheral arterial diseases in obese persons: Results from the national health and nutrition examination survey 1999–2004. Atherosclerosis, 218(1), 200–206. https://doi.org/10.1016/j.atherosclerosis.2011.04.044
doi: 10.1016/j.atherosclerosis.2011.04.044
pubmed: 21620405
Aminov, Z., Haase, R., Rej, R., Schymura, M. J., Santiago-Rivera, A., Morse, G., & Environment, A. T. F. (2016). Diabetes prevalence in relation to serum concentrations of polychlorinated biphenyl (PCB) congener groups and three chlorinated pesticides in a Native American population. Environmental Health Perspectives, 124(9), 1376–1383. https://doi.org/10.1289/ehp.1509902
doi: 10.1289/ehp.1509902
pubmed: 27035469
pmcid: 5010411
Perkins, J. T., Petriello, M. C., Newsome, B. J., & Hennig, B. (2016). Polychlorinated biphenyls and links to cardiovascular disease. Environmental Sciences and Polluttion Research International, 23(3), 2160–2172. https://doi.org/10.1007/s11356-015-4479-6
doi: 10.1007/s11356-015-4479-6
Hu, X. F., Singh, K., & Chan, H. M. (2018). Mercury exposure, blood pressure, and hypertension: A systematic review and dose–response meta-analysis. Environmental Health Perspectives, 126(07), 076002. https://doi.org/10.1289/EHP2863
doi: 10.1289/EHP2863
pubmed: 30073953
pmcid: 6108832
Le Magueresse-Battistoni, B., Vidal, H., & Naville, D. (2018). Environmental pollutants and metabolic disorders: The multi-exposure scenario of life. Frontier in Endocrinology (Lausanne), 9, 582. https://doi.org/10.3389/fendo.2018.00582
doi: 10.3389/fendo.2018.00582
Baker, J. R. E. L., Landrigan, P. J., Glueck, C. J., Zack, J. R. M. M., Liddl, J. A., Burse, V. W., & Needham, L. L. (1980). Metabolic consequences of exposure to polychlorinated biphenyls (PCB) in sewage sludge. American Journal of Epidemiology., 112(4), 553–563. https://doi.org/10.1093/oxfordjournals.aje.a113024
doi: 10.1093/oxfordjournals.aje.a113024
pubmed: 6775528
Goncharov, A., Haase, R. F., Santiago-Rivera, A., Morse, G., McCaffrey, R. J., Rej, R., & Environment, A. T. F. (2008). High serum PCBs are associated with elevation of serum lipids and cardiovascular disease in a Native American population. Environmental Research, 106(2), 226–239. https://doi.org/10.1016/j.envres.2007.10.006
doi: 10.1016/j.envres.2007.10.006
pubmed: 18054906
Kreiss, K., Zack, M. M., Kimbrough, R. D., Needham, L. L., Smrek, A. L., & Jones, B. T. (1981). Association of blood pressure and polychlorinated biphenyl levels. Journal of the American Medical Association, 245(24), 2505–2509. https://doi.org/10.1001/jama.1981.03310490023017
doi: 10.1001/jama.1981.03310490023017
pubmed: 6785463
Raffetti, E., Donato, F., Speziani, F., Scarcella, C., Gaia, A., & Magoni, M. (2018). Polychlorinated biphenyls (PCBs) exposure and cardiovascular, endocrine and metabolic diseases: A population-based cohort study in a North Italian highly polluted area. Environmental International, 120, 215–222. https://doi.org/10.1016/j.envint.2018.08.022
doi: 10.1016/j.envint.2018.08.022
Sergeev, A. V., & Carpenter, D. O. (2005). Hospitalization rates for coronary heart disease in relation to residence near areas contaminated with persistent organic pollutants and other pollutants. Environmental Health Perspectives, 113(6), 756–761. https://doi.org/10.1289/ehp.7595
doi: 10.1289/ehp.7595
pubmed: 15929900
pmcid: 1257602
Sørensen, N., Murata, K., Budtz-Jørgensen, E., Weihe, P., & Grandjean, P. (1999). Prenatal methylmercury exposure as a cardiovascular risk factor at seven years of age. Epidemiology, 10(4), 370–375.
doi: 10.1097/00001648-199907000-00006
Fillion, M., Mergler, D., Passos, C. J. S., Larribe, F., Lemire, M., & Guimarães, J. R. D. (2006). A preliminary study of mercury exposure and blood pressure in the Brazilian Amazon. Environmental Health, 5(1), 29. https://doi.org/10.1186/1476-069X-5-29
doi: 10.1186/1476-069X-5-29
pubmed: 17032453
pmcid: 1617089
Stern, A. H. (2005). A review of the studies of the cardiovascular health effects of methylmercury with consideration of their suitability for risk assessment. Environmental Research, 98(1), 133–142. https://doi.org/10.1016/j.envres.2004.07.016
doi: 10.1016/j.envres.2004.07.016
pubmed: 15721894
Valera, B., Dewailly, E., & Poirier, P. (2008). Cardiac autonomic activity and blood pressure among Nunavik Inuit adults exposed to environmental mercury: A cross-sectional study. Environmental Health, 7(1), 29. https://doi.org/10.1186/1476-069X-7-29
doi: 10.1186/1476-069X-7-29
pubmed: 18538022
pmcid: 2443124
Jin, X., Hidiroglou, N., Lok, E., Taylor, M., Kapal, K., Ross, N., Sarafin, K., Lau, A., De Souza, A., Chan, H. M., & Mehta, R. (2012). Dietary selenium (Se) and vitamin E (V(E)) supplementation modulated methylmercury-mediated changes in markers of cardiovascular diseases in rats. Cardiovascular Toxicology, 12(1), 10–24. https://doi.org/10.1007/s12012-011-9134-y
doi: 10.1007/s12012-011-9134-y
pubmed: 21822669
Hu, X. F., Singh, K., Kenny, T. A., & Chan, H. M. (2019). Prevalence of heart attack and stroke and associated risk factors among Inuit in Canada: A comparison with the general Canadian population. International Journal of Hygiene and Environmental Health, 222(2), 319–326. https://doi.org/10.1016/j.ijheh.2018.12.003
doi: 10.1016/j.ijheh.2018.12.003
pubmed: 30578133
Johnson, J. A., Vermeulen, S. U., Toth, E. L., Hemmelgarn, B. R., Ralph-Campbel, K., Hugel, G., & Crowshoe, L. (2009). Increasing incidence and prevalence of diabetes among the status aboriginal population in urban and rural Alberta, 1995–2006. Canadian Journal of Public Health, 100(3), 231–236. https://doi.org/10.1007/BF03405547
doi: 10.1007/BF03405547
pubmed: 19507729
pmcid: 6973863
Ralph-Campbell, K., Oster, R. T., Connor, T., Pick, M., Pohar, S., Thompson, P., & Cardinal-Lamouche, S. (2009). Increasing rates of diabetes and cardiovascular risk in Métis settlements in northern Alberta. International Journal of Circumpolar Health, 68(5), 433–442. https://doi.org/10.3402/ijch.v68i5.17382
doi: 10.3402/ijch.v68i5.17382
pubmed: 20044962
Rehm, J., & Roerecke, M. (2017). Cardiovascular effects of alcohol consumption. Trends in Cardiovascular Medicine, 27(8), 534–538. https://doi.org/10.1016/j.tcm.2017.06.002
doi: 10.1016/j.tcm.2017.06.002
pubmed: 28735784
Shield, K. D., Parry, C., & Rehm, J. (2013). Chronic diseases and conditions related to alcohol use. Alcohol Research, 35(2), 155–173.
pubmed: 24881324
Willows, N., Johnson-Down, L., Kenny, T. A., Chan, H. M., & Batal, M. (2019). Modelling optimal diets for quality and cost: Examples from Inuit and First Nations communities in Canada. Applied Physiology, Nutrition, and Metabolism, 44(7), 696–703. https://doi.org/10.1139/apnm-2018-0624
doi: 10.1139/apnm-2018-0624
pubmed: 30566364
Mailloux, R. J., Florian, M., Chen, Q., Yan, J., Petrov, I., Coughlan, M. C., Laziyan, M., Caldwell, D., Lalande, M., Patry, D., Gagnon, C., Sarafin, K., Truong, J., Chan, H. M., Ratnayake, N., Li, N., Willmore, W. G., & Jin, X. (2014). Exposure to a northern contaminant mixture (NCM) alters hepatic energy and lipid metabolism exacerbating hepatic steatosis in obese JCR rats. PLoS ONE, 9(9), e106832. https://doi.org/10.1371/journal.pone.0106832
doi: 10.1371/journal.pone.0106832
pubmed: 25222487
pmcid: 4164366
Mailloux, R., Fu, A., Florian, M., Petrov, I., Chen, Q., Coughlan, M. C., Laziyan, M., Yan, J., Caldwell, D., Patry, D., Lalande, M., Wang, G. S., Willmore, W., & Jin, X. (2015). A Northern contaminant mixture impairs pancreas function in obese and lean JCR rats and inhibits insulin secretion in MIN6 cells. Toxicology, 334, 81–93. https://doi.org/10.1016/j.tox.2015.06.001
doi: 10.1016/j.tox.2015.06.001
pubmed: 26066519
Russell, J. C., Graham, S. E., & Richardson, M. (1998). Cardiovascular disease in the JCR:LA-cp rat. Molecular and Cellular Biochemistry, 188(1–2), 113–126.
doi: 10.1023/A:1006828724405
Dewailly, E., Ayotte, P., Pereg, D., & Dery, S. (2006) Exposure to heavy metals and persistent organic pollutants in Nunavik: The Nunavik health study (human health). Synopsis of Research, 2005–2006 Northern Contaminants Program, 44–64.
Michaud, K., Basso, C., d’Amati, G., Michaud, K., Basso, C., d’Amati, G., Giordano, C., Kholová, I., Preston, S. D., Rizzo, S., Sabatasso, S., Sheppard, M. N., Vink, A., van der Wal, A. C., Association for European Cardiovascular Pathology. (2020). Diagnosis of myocardial infarction at autopsy: AECVP reappraisal in the light of the current clinical classification. Virchows Archiv, 476, 179–194. https://doi.org/10.1007/s00428-019-02662-1
doi: 10.1007/s00428-019-02662-1
pubmed: 31522288
Shabana, S. S. U., & Sarwar, S. (2020). The abnormal lipid profile in obesity and coronary heart disease (CHD) in Pakistani subjects. Lipids in Health and Diseases., 19(1), 73. https://doi.org/10.1186/s12944-020-01248-0
doi: 10.1186/s12944-020-01248-0
Gany, A., & Aljaffar, Y. (2018). A study of serum lipid profile among obese and non-obese individuals: A hospital-based study from Karbala, Iraq. International Journal of Contemporary Medicine Research, 5(4), D17–D20. https://doi.org/10.21276/ijcmr.2018.5.4.11
doi: 10.21276/ijcmr.2018.5.4.11
Esser, N., Legrand-Poels, S., Piette, J., Scheen, A. J., & Paquot, N. (2014). Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Research and Clinical Practice, 105(2), 141–150. https://doi.org/10.1016/j.diabres.2014.04.006
doi: 10.1016/j.diabres.2014.04.006
pubmed: 24798950
Unamuno, X., Gómez-Ambrosi, J., Rodríguez, A., Becerril, S., Frühbeck, G., & Catalán, V. (2018). Adipokine dysregulation and adipose tissue inflammation in human obesity. European Journal Clinical Investigation, 48(9), e12997. https://doi.org/10.1111/eci.12997
doi: 10.1111/eci.12997
Hanley, A. J., Retnakaran, R., Qi, Y., Gerstein, H. C., Perkins, B., Raboud, J., Harris, S. B., & Zinman, B. (2009). Association of hematological parameters with insulin resistance and beta-cell dysfunction in nondiabetic subjects. Journal of Clinical Endocrinology and Metabolism, 94(10), 3824–3832. https://doi.org/10.1210/jc.2009-0719
doi: 10.1210/jc.2009-0719
pubmed: 19622625
Vuong, J., Qiu, Y., La, M., Clarke, G., Swinkels, D. W., & Cembrowski, G. (2014). Reference intervals of complete blood count constituents are highly correlated to waist circumference: Should obese patients have their own “normal values?” American Journal of Hematology, 89(7), 671–677. https://doi.org/10.1002/ajh.23713
doi: 10.1002/ajh.23713
pubmed: 24644218
Gebrie, A., Gnanasekaran, N., Menon, M., Sisay, M., & Zegeye, A. (2018). Evaluation of lipid profiles and hematological parameters in hypertensive patients: Laboratory-based cross-sectional study. SAGE Open Medicine, 6, 2050312118756663. https://doi.org/10.1177/2050312118756663
doi: 10.1177/2050312118756663
pubmed: 29468066
pmcid: 5813853
Singh, S., Dwivedi, A., & Mittal, P. C. (2018). Anisocytosis is associated with high body mass index and poor adaptation to oxidative stress in obese patients with type 2 diabetes mellitus. Journal of Life Sciences, 10(2), 123–131. https://doi.org/10.31901/24566306.2018/10.02.232
doi: 10.31901/24566306.2018/10.02.232
Thongprayoon, C., Cheungpasitporn, W., & Kashani, K. (2016). Serum creatinine level, a surrogate of muscle mass, predicts mortality in critically ill patients. Journal of Thoracic Diseases, 8(5), E305-311. https://doi.org/10.21037/jtd.2016.03.62
doi: 10.21037/jtd.2016.03.62
Schutte, J. E., Longhurst, J. C., Gaffney, F. A., Bastian, C., & Blomqvist, C. G. (1981). Total plasma creatinine: An accurate measure of total striated muscle mass. Journal of Applied Physiology Respirational, Environmental, and Exercise Physiology, 51, 762–766. https://doi.org/10.1152/jappl.1981.51.3.762
doi: 10.1152/jappl.1981.51.3.762
Park, J., Mehrotra, R., Rhee, C. M., et al. (2013). Serum creatinine level, a surrogate of muscle mass, predicts mortality in peritoneal dialysis patients. Nephrology Dialysis and Transplantation, 28, 2146–2155. https://doi.org/10.1093/ndt/gft213
doi: 10.1093/ndt/gft213
Chaudhari, U., Newcomb, J., & Hansen, B. (2018). Serum creatinine progressively decreases with obesity and type 2 diabetes in nonhuman primates. Diabetes. https://doi.org/10.2337/db18-1931-P
doi: 10.2337/db18-1931-P
Cuthbert, J. J., Pellicori, P., Rigby, A., Pan, D., Kazmi, S., Shah, P., & Clark, A. L. (2018). Low serum chloride in patients with chronic heart failure: Clinical associations and prognostic significance. European Journal of Heart Failure, 20(10), 1426–1435. https://doi.org/10.1002/ejhf.1247
doi: 10.1002/ejhf.1247
pubmed: 29943886
De Bacquer, D., De Backer, G., De Buyzere, M., & Kornitzer, M. (1998). Is low serum chloride level a risk factor for cardiovascular mortality? Journal of Cardiovascular Risk, 5(3), 177–184. https://doi.org/10.1177/174182679800500307
doi: 10.1177/174182679800500307
pubmed: 10201555
Pfortmueller, C. A., Uehlinger, D., von Haehling, S., & Schefold, J. C. (2018). Serum chloride levels in critical illness-the hidden story. Intensive Care Medicine Experimental, 6(1), 10. https://doi.org/10.1186/s40635-018-0174-5
doi: 10.1186/s40635-018-0174-5
pubmed: 29654387
pmcid: 5899079
McCallum, L., Lip, S., & Padmanabhan, S. (2015). The hidden hand of chloride in hypertension. Pflügers Archiv - European Journal of Physiology, 467, 595–603. https://doi.org/10.1007/s00424-015-1690-8
doi: 10.1007/s00424-015-1690-8
pubmed: 25619794
pmcid: 4325190
Piani, F., Cicero, A. F. G., & Borghi, C. (2021). Uric acid and hypertension: Prognostic role and guide for treatment. Journal Clinical Medicine, 10(3), 448. https://doi.org/10.3390/jcm10030448
doi: 10.3390/jcm10030448
Feig, D. I., Kang, D. H., & Johnson, R. J. (2008). Uric acid and cardiovascular risk. The New England Journal of Medicine, 359, 1811–1821. https://doi.org/10.1056/NEJMra0800885
doi: 10.1056/NEJMra0800885
pubmed: 18946066
pmcid: 2684330
Cicero, A. F. G., Fogacci, F., Giovannini, M., Grandi, E., D’Addato, S., Borghi, C., Brisighella Heart Study Group. (2019). Interaction between low-density lipoprotein-cholesterolaemia, serum uric level and incident hypertension. Journal of Hypertension, 37(4), 728–731. https://doi.org/10.1097/HJH.0000000000001927
doi: 10.1097/HJH.0000000000001927
pubmed: 30817453
Giles, T. D., Sander, G. E., Nossaman, B. D., & Kadowitz, P. J. (2012). Impaired vasodilation in the pathogenesis of hypertension: Focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandins. Journal of Clinical Hypertension (Greenwich), 14(4), 198–205. https://doi.org/10.1111/j.1751-7176.2012.00606
doi: 10.1111/j.1751-7176.2012.00606
Rahman, M. S. (2019). Prostacyclin: A major prostaglandin in the regulation of adipose tissue development. Journal of Cellular Physiology, 234(4), 3254–3262. https://doi.org/10.1002/jcp.26932
doi: 10.1002/jcp.26932
pubmed: 30431153
Oh, R. C., Hustead, T. R., Ali, S. M., & Pantsari, M. W. (2017). Mildly elevated liver transaminase levels: Causes and evaluation. American Family Physician, 96(11), 709–715.
pubmed: 29431403
Morisco, F., Pagliaro, L., Caporaso, N., Bianco, E., Sagliocca, L., Fargion, S., Smedile, A., Salvagnini, M., & Mele, A. (2008). Consensus recommendations for managing asymptomatic persistent non-virus non-alcohol related elevation of aminotransferase levels: Suggestions for diagnostic procedures and monitoring. Digestive Liver Diseases, 40(7), 585–598. https://doi.org/10.1016/j.dld.2008.02.003
doi: 10.1016/j.dld.2008.02.003
Yu, K. J., Zhang, M. J., Li, Y., & Wang, R. T. (2014). Increased whole blood viscosity associated with arterial stiffness in patients with non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology, 29(3), 540–544. https://doi.org/10.1111/jgh.12368
doi: 10.1111/jgh.12368
pubmed: 23981121
Trak-Smayra, V., Dargere, D., Noun, R., Albuquerque, M., Yaghi, C., Gannagé-Yared, M. H., Bedossa, P., & Paradis, V. (2009). Serum proteomic profiling of obese patients: Correlation with liver pathology and evolution after bariatric surgery. Gut, 58(6), 825–832. https://doi.org/10.1136/gut.2007.140087
doi: 10.1136/gut.2007.140087
pubmed: 18403495
Chen, S., Guo, X., Zhang, X., Yu, S., Yang, H., Jiang, M., Sun, G., & Sun, Y. (2015). Association between elevated serum alanine aminotransferase and cardiometabolic risk factors in rural Chinese population: A cross-sectional study. BMC Cardiovascular Disorders, 15, 65. https://doi.org/10.1186/s12872-015-0060-y
doi: 10.1186/s12872-015-0060-y
pubmed: 26160405
pmcid: 4702363
Cao, Y., Pan, Q., Cai, W., Shen, F., Chen, G. Y., Xu, L. M., & Fan, J. G. (2016). Modulation of gut microbiota by berberine improves steatohepatitis in high-fat diet-fed BALB/C mice. Archives of Iranian Medicine, 19, 197–203.
pubmed: 26923892
Shen, F., Zheng, R. D., Sun, X. Q., Ding, W. J., Wang, X. Y., & Fan, J. G. (2017). Gut microbiota dysbiosis in patients with nonalcoholic fatty liver disease. Hepatobiliary and Pancreatic Diseases International, 16, 375–381. https://doi.org/10.1016/S1499-3872(17)60019-5
doi: 10.1016/S1499-3872(17)60019-5
pubmed: 28823367
Zhou, D., & Fan, J. G. (2019). Microbial metabolites in non-alcoholic fatty liver disease. World Journal of Gastroenterology, 25(17), 2019–2028. https://doi.org/10.3748/wjg.v25.i17.2019
doi: 10.3748/wjg.v25.i17.2019
pubmed: 31114130
pmcid: 6506577
Engstler, A. J., Aumiller, T., Degen, C., Dürr, M., Weiss, E., Maier, I. B., Schattenberg, J. M., Jin, C. J., Sellmann, C., Bergheim, I., et al. (2016). Insulin resistance alters hepatic ethanol metabolism: Studies in mice and children with non-alcoholic fatty liver disease. Gut, 65, 1564–1571. https://doi.org/10.1136/gutjnl-2014-308379
doi: 10.1136/gutjnl-2014-308379
pubmed: 26006114
Brewster, L. M., Mairuhu, G., Bindraban, N. R., Koopmans, R. P., Clark, J. F., & van Montfrans, G. A. (2006). Creatine kinase activity is associated with blood pressure. Circulation, 114(19), 2034–2039. https://doi.org/10.1161/CIRCULATIONAHA.105.584490
doi: 10.1161/CIRCULATIONAHA.105.584490
pubmed: 17075013
Brewster, L. M., Karamat, F. A., & van Montfrans, G. A. (2019). Creatine kinase and blood pressure: A systematic review. Medical Sciences (Basel), 7(4), 58. https://doi.org/10.3390/medsci7040058
doi: 10.3390/medsci7040058
Watanabe, M., Okamura, T., Kokubo, Y., Higashiyama, A., & Okayama, A. (2009). Elevated serum creatine kinase predicts first-ever myocardial infarction: A 12-year population-based cohort study in Japan, the Suita study. International Journal of Epidemiology, 38(6), 1571–1579. https://doi.org/10.1093/ije/dyp212
doi: 10.1093/ije/dyp212
pubmed: 19556328
Matschinsky, F. M., & Wilson, D. F. (2019). The central role of glucokinase in glucose homeostasis: A perspective 50 years after demonstrating the presence of the enzyme in islets of langerhans. Frontier in Physiology, 10, 148. https://doi.org/10.3389/fphys.2019.00148
doi: 10.3389/fphys.2019.00148
Matschinsky, F. M. (2013). GKAs for diabetes therapy: Why no clinically useful drug after two decades of trying? Trends in Pharmacological Sciences, 34, 90–99. https://doi.org/10.1016/j.tips.2012.11.007
doi: 10.1016/j.tips.2012.11.007
pubmed: 23305809
Arriarán, S., Agnelli, S., Sabater, D., Remesar, X., Fernández-López, J. A., & Alemany, M. (2015). Evidences of basal lactate production in the main white adipose tissue sites of rats. Effects of sex and a cafeteria diet. PLoS ONE, 10(3), e0119572. https://doi.org/10.1371/journal.pone.0119572
doi: 10.1371/journal.pone.0119572
pubmed: 25741703
pmcid: 4351194
Moon, C. M., Oh, C. H., Ahn, K. Y., Yang, J. S., Kim, J. Y., Shin, S. S., Lim, H. S., Heo, S. H., Seon, H. J., Kim, J. W., & Jeong, G. W. (2017). Metabolic biomarkers for non-alcoholic fatty liver disease induced by high-fat diet: In vivo magnetic resonance spectroscopy of hyperpolarized [1-13C] pyruvate. Biochemical Biophysical Research Communications, 482(1), 112–119. https://doi.org/10.1016/j.bbrc.2016.08.118
doi: 10.1016/j.bbrc.2016.08.118
pubmed: 27562716
Andersen, T., Christoffersen, P., & Gluud, C. (1984). The liver in consecutive patients with morbid obesity: A clinical, morphological, and biochemical study. International Journal of Obesity, 8(2), 107–115.
pubmed: 6724792
Choi, J. W. (2003). Association between elevated serum hepatic enzyme activity and total body fat in obese humans. Annals of Clinical Laboratory Sciences, 33(3), 257–264.
Jeon, J., Morris, J. S., & Park, K. (2021). Toenail mercury levels positively correlate with obesity and abdominal obesity among Korean adults. Journal of Trace Elements in Medicine and Biology, 64, 126678. https://doi.org/10.1016/j.jtemb.2020.126678
doi: 10.1016/j.jtemb.2020.126678
pubmed: 33249372
Wang, X., Mukherjee, B., & Park, S. K. (2018). Associations of cumulative exposure to heavy metal mixtures with obesity and its comorbidities among U.S. adults in NHANES 2003–2014. Environment International, 121(Pt 1), 683–694. https://doi.org/10.1016/j.envint.2018.09.035
doi: 10.1016/j.envint.2018.09.035
pubmed: 30316184
pmcid: 6268112
Cho, H. W., Kim, S. H., & Park, M. J. (2020). An association of blood mercury levels and hypercholesterolemia among Korean adolescents. Sciences of Total Environment, 709, 135965. https://doi.org/10.1016/j.scitotenv.2019.135965
doi: 10.1016/j.scitotenv.2019.135965
Lee, S., Cho, S. R., Jeong, I., Park, J. B., Shin, M. Y., Kim, S., & Kim, J. H. (2020). Mercury exposure and associations with hyperlipidemia and elevated liver enzymes: A nationwide cross-sectional survey. Toxics, 8(3), 47. https://doi.org/10.3390/toxics8030047
doi: 10.3390/toxics8030047
pmcid: 7560241
Emery, M. G., Fisher, J. M., Chien, J. Y., Kharasch, E. D., Dellinger, E. P., Kowdley, K. V., & Thummel, K. E. (2003). CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology, 38(2), 428–435. https://doi.org/10.1053/jhep.2003.50342
doi: 10.1053/jhep.2003.50342
pubmed: 12883487
Chiu, K., Warner, G., Nowak, R. A., Flaws, J. A., & Mei, W. (2020). The impact of environmental chemicals on the gut microbiome. Toxicological Sciences, 176(2), 253–284. https://doi.org/10.1093/toxsci/kfaa065
doi: 10.1093/toxsci/kfaa065
pubmed: 32392306
pmcid: 7416318
Claus, S., Guillou, H., & Ellero-Simatos, S. (2016). The gut microbiota: A major player in the toxicity of environmental pollutants? Biofilms and Microbiomes, 2, 16003. https://doi.org/10.1038/npjbiofilms.2016.3
doi: 10.1038/npjbiofilms.2016.3
pubmed: 28721242
pmcid: 5515271
Yuan, J., Chen, C., Cui, J., Lu, J., Yan, C., Wei, X., Zhao, X., Li, N., Li, S., Xue, G., Cheng, W., Li, B., Li, H., Lin, W., Tian, C., Zhao, J., Han, J., An, D., Zhang, Q., … Liu, D. (2019). Fatty liver disease caused by high-alcohol-producing klebsiella pneumoniae. Cell Metabolism, 30(4), 675-688.e7. https://doi.org/10.1016/j.cmet.2019.08.018
doi: 10.1016/j.cmet.2019.08.018
pubmed: 31543403